Title:Omalizumab for the Treatment of Persistent Drug Induced Urticaria Elicited by Thienopyridines: A Case Report
VOLUME: 19 ISSUE: 3
Author(s):Gianfranco Calogiuri*, Eustachio Nettis, Alessandro Mandurino-Mirizzi, Elisabetta Di Leo, Luigi Macchia, Caterina Foti, Angelo Vacca and Nicholas G. Kounis
Affiliation:Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Bari, Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Bari, Cardiology Department, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Section of Allergy and Clinical Immunology, Unit of Internal Medicine-"F. Miulli" Hospital, Acquaviva Delle Fonti, Bari, Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Bari, Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, 70124 Bari, Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, University of Bari "Aldo Moro" Medical School, Bari, Department of Cardiology, University of Patras Medical School, Patras
Keywords:Clopidogrel, omalizumab, prasugrel, thienopyridines, ticagrelor, urticaria.
Abstract:The anti-IgE Omalizumab may be helpful to treat clopidogrel hypersensitivity
without stopping thienopyridine administration in patients requirining continuous antiplatellet
therapy after coronary stent placement.
